NNC0114-0005
NNC0114-0005 is a monoclonal antibody that has been investigated for its potential therapeutic effects in the treatment of inflammatory diseases. It is a humanized antibody designed to target and neutralize specific cytokines involved in the inflammatory process.
Mechanism of Action[edit | edit source]
NNC0114-0005 functions by binding to and inhibiting the activity of interleukin-21 (IL-21), a cytokine that plays a crucial role in the regulation of immune responses. IL-21 is involved in the proliferation and differentiation of T cells, B cells, and natural killer (NK) cells. By blocking IL-21, NNC0114-0005 aims to reduce the inflammatory response and ameliorate symptoms associated with autoimmune and inflammatory conditions.
Clinical Development[edit | edit source]
NNC0114-0005 has undergone various stages of clinical trials to assess its safety, efficacy, and pharmacokinetics. Early-phase trials have focused on determining the optimal dosing regimen and evaluating the antibody's impact on biomarkers of inflammation.
Phase I Trials[edit | edit source]
Phase I clinical trials for NNC0114-0005 were primarily concerned with assessing the safety profile of the drug in healthy volunteers. These studies helped establish the pharmacokinetic parameters and provided initial data on the drug's tolerability.
Phase II Trials[edit | edit source]
In Phase II trials, NNC0114-0005 was tested in patients with specific inflammatory diseases, such as rheumatoid arthritis and systemic lupus erythematosus. These studies aimed to evaluate the efficacy of the drug in reducing disease activity and improving clinical outcomes.
Potential Applications[edit | edit source]
The primary focus of NNC0114-0005 is on autoimmune diseases where IL-21 plays a significant role. Conditions such as rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease are potential targets for this therapeutic approach.
Safety and Side Effects[edit | edit source]
As with any monoclonal antibody therapy, potential side effects of NNC0114-0005 include infusion reactions, increased risk of infections, and hypersensitivity reactions. Ongoing studies continue to monitor the long-term safety of the drug in various patient populations.
Also see[edit | edit source]
- Monoclonal antibody therapy
- Interleukin-21
- Autoimmune disease
- Rheumatoid arthritis
- Systemic lupus erythematosus
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
